These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16848380)

  • 21. Treating proteinuria in a diabetic patient despite hyperkalaemia due to hyporeninaemic hypoaldosteronism.
    van Nieuwkoop C; Ijpelaar DH; Bolk JH
    Neth J Med; 2007 Feb; 65(2):75-7. PubMed ID: 17379933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal and retinal effects of enalapril and losartan in type 1 diabetes.
    Katavetin P; Katavetin P
    N Engl J Med; 2009 Oct; 361(14):1410-1; author reply 1411. PubMed ID: 19802919
    [No Abstract]   [Full Text] [Related]  

  • 23. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.
    Abuissa H; O'Keefe J
    Diabetes Obes Metab; 2008 Dec; 10(12):1157-66. PubMed ID: 18494810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kidney disease in diabetology: lessons from 2008.
    Schernthaner G
    Nephrol Dial Transplant; 2009 Feb; 24(2):396-9. PubMed ID: 19144896
    [No Abstract]   [Full Text] [Related]  

  • 25. Antihypertensive treatment in nephropathy of type II diabetes: role of the pharmacological blockade of the renin-angiotensin system.
    Rodby RA
    Nephrol Dial Transplant; 1997 Jun; 12(6):1095-6. PubMed ID: 9198032
    [No Abstract]   [Full Text] [Related]  

  • 26. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
    Dussol B; Berland Y
    Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibiting the renin-angiotensin system in patients with type 1 diabetes: is it worth it?
    Duka I; Bakris G
    Pol Arch Med Wewn; 2009 Nov; 119(11):692-3. PubMed ID: 19920790
    [No Abstract]   [Full Text] [Related]  

  • 28. Strategies for preventing diabetic nephropathy.
    Raymond JR; Arthur JM; Kovalik E
    N C Med J; 1994 Aug; 55(8):362-9. PubMed ID: 7935886
    [No Abstract]   [Full Text] [Related]  

  • 29. [The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy].
    Shamkhlova MSh; Trubitsyna NP; Katsaia GV; Goncharov NP; Malysheva NM; Il'in AV; Nikankina LV; Koshel' LV; Shestakova MV
    Ter Arkh; 2008; 80(1):49-52. PubMed ID: 18326228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should all diabetic patients take ACE inhibitors, even those without proteinuria?
    Hoogwerf BJ
    Cleve Clin J Med; 1999 Apr; 66(4):208-9. PubMed ID: 10199056
    [No Abstract]   [Full Text] [Related]  

  • 31. ACE inhibitors vs. ARBs for patients with diabetic kidney disease.
    Bailey J
    Am Fam Physician; 2007 Jul; 76(1):68-9. PubMed ID: 17668841
    [No Abstract]   [Full Text] [Related]  

  • 32. [Use of angiotensin converting enzyme inhibitors in nephrology].
    Stefanović V; Ivić M; Bogićević M
    Srp Arh Celok Lek; 1994; 122(7-8):228-30. PubMed ID: 17974394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease.
    Weir MR
    Postgrad Med; 2009 Jan; 121(1):96-103. PubMed ID: 19179817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Renal protection in the diabetic patient with ACE inhibitors].
    Pérez Blanco FJ; Rodríguez Cuartero A
    Rev Clin Esp; 1992 Nov; 191(7):393-4. PubMed ID: 1475469
    [No Abstract]   [Full Text] [Related]  

  • 35. [Need of tight blood pressure control in type 2 diabetes. The intervention study ADVANCE gives clear information].
    Nilsson PM
    Lakartidningen; 2007 Oct 17-23; 104(42):3028-9. PubMed ID: 17985709
    [No Abstract]   [Full Text] [Related]  

  • 36. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
    Jia ZH; Liu ZH; Zheng JM; Zeng CH; Li LS
    Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
    Agha A; Bashir K; Anwar E
    Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating hypertension in the patient with overt diabetic nephropathy.
    Lewis EJ
    Semin Nephrol; 2007 Mar; 27(2):182-94. PubMed ID: 17418687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of progression of kidney disease: diabetic nephropathy - CARI guidelines.
    Nicholls K
    Aust Fam Physician; 2007 Mar; 36(3):137-8. PubMed ID: 17339976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K; Miller NH
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.